{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:48Z","timestamp":1791296568297,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The somatic JAK2 valine-to-phenylalanine (V617F) mutation has been detected in up to 90% of patients with polycythemia and in a sizeable proportion of patients with other myeloproliferative disorders such as essential thrombocythemia and idiopathic myelofibrosis. Suppressor of cytokine signaling 3 (SOCS3) is known to be a strong negative regulator of erythropoietin (EPO) signaling through interaction with both the EPO receptor (EPOR) and JAK2. We report here that JAK2 V617F cannot be regulated and that its activation is actually potentiated in the presence of SOCS3. Instead of acting as a suppressor, SOCS3 enhanced the proliferation of cells expressing both JAK2 V617F and EPOR. Additionally, although SOCS1 and SOCS2 are degraded in the presence of JAK2 V617F, turnover of SOCS3 is inhibited by the JAK2 mutant kinase and this correlated with marked tyrosine phosphorylation of SOCS3 protein. We also observed constitutive tyrosine phosphorylation of SOCS3 in peripheral blood mononuclear cells (PBMCs) derived from patients homozygous for the JAK2 V617F mutant. These findings suggest that the JAK2 V617F has overcome normal SOCS regulation by hyperphosphorylating SOCS3, rendering it unable to inhibit the mutant kinase. Thus, JAK2 V617F may even exploit SOCS3 to potentiate its myeloproliferative capacity.<\/jats:p>","DOI":"10.1182\/blood-2006-08-039735","type":"journal-article","created":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T01:43:55Z","timestamp":1172195035000},"page":"4924-4929","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["The myeloproliferative disorder\u2013associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3"],"prefix":"10.1182","volume":"109","author":[{"given":"Michelle B.","family":"Hookham","sequence":"first","affiliation":[{"name":"Infection and Immunity Group, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Elliott","sequence":"additional","affiliation":[{"name":"Infection and Immunity Group, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Suessmuth","sequence":"additional","affiliation":[{"name":"Infection and Immunity Group, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Staerk","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"Christian de Duve Institute for Cellular Pathology, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alister C.","family":"Ward","sequence":"additional","affiliation":[{"name":"School of Life and Environmental Science, Deakin University, Burwood, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Vainchenker","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) Unit\u00e9 (U) 790, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Percy","sequence":"additional","affiliation":[{"name":"Haematology, Belfast City Hospital, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[{"name":"Haematology, Belfast City Hospital, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"Christian de Duve Institute for Cellular Pathology, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Infection and Immunity Group, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713122963900_B1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111713122963900_B2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111713122963900_B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111713122963900_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111713122963900_B5","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera.","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"2019111713122963900_B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"key":"2019111713122963900_B7","doi-asserted-by":"crossref","first-page":"41893","DOI":"10.1074\/jbc.C500358200","article-title":"JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.","volume":"280","author":"Staerk","year":"2005","journal-title":"J Biol Chem"},{"key":"2019111713122963900_B8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/emboj\/18.2.375","article-title":"Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction.","volume":"18","author":"Nicholson","year":"1999","journal-title":"EMBO J"},{"key":"2019111713122963900_B9","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/MCB.21.10.3547-3557.2001","article-title":"Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.","volume":"21","author":"Frantsve","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2019111713122963900_B10","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/MCB.22.10.3316-3326.2002","article-title":"Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.","volume":"22","author":"Ungureanu","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2019111713122963900_B11","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1046\/j.1432-1033.2002.02916.x","article-title":"A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor.","volume":"269","author":"Hortner","year":"2002","journal-title":"Eur J Biochem"},{"key":"2019111713122963900_B12","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1128\/MCB.19.7.4980","article-title":"SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.","volume":"19","author":"Cohney","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2019111713122963900_B13","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1073\/pnas.100135197","article-title":"Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.","volume":"97","author":"Nicholson","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713122963900_B14","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713122963900_B15","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.4049\/jimmunol.173.5.3243","article-title":"The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression.","volume":"173","author":"Stevenson","year":"2004","journal-title":"J Immunol"},{"key":"2019111713122963900_B16","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1074\/jbc.273.12.6916","article-title":"Granzyme release and caspase activation in activated human T-lymphocytes.","volume":"273","author":"Zapata","year":"1998","journal-title":"J Biol Chem"},{"key":"2019111713122963900_B17","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1128\/MCB.25.20.9115-9126.2005","article-title":"SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.","volume":"25","author":"Tannahill","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2019111713122963900_B18","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1101\/gad.1252404","article-title":"VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.","volume":"18","author":"Kamura","year":"2004","journal-title":"Genes Dev"},{"key":"2019111713122963900_B19","doi-asserted-by":"crossref","first-page":"31972","DOI":"10.1074\/jbc.M303170200","article-title":"Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation.","volume":"278","author":"Haan","year":"2003","journal-title":"J Biol Chem"},{"key":"2019111713122963900_B20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/35074525","article-title":"Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras.","volume":"3","author":"Cacalano","year":"2001","journal-title":"Nat Cell Biol"},{"key":"2019111713122963900_B21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molcel.2004.06.041","article-title":"v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells.","volume":"15","author":"Limnander","year":"2004","journal-title":"Mol Cell"},{"key":"2019111713122963900_B22","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1073\/pnas.042035699","article-title":"Pim serine\/threonine kinases regulate the stability of Socs-1 protein.","volume":"99","author":"Chen","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713122963900_B23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.emboj.7601640","article-title":"Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor.","volume":"26","author":"Irandoust","year":"2007","journal-title":"EMBO J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/11\/4924\/1480010\/zh801107004924.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/11\/4924\/1480010\/zh801107004924.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T18:12:40Z","timestamp":1574014360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/11\/4924\/23105\/The-myeloproliferative-disorderassociated-JAK2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-08-039735","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}